Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
Alimentary Pharmacology & Therapeutics · 2024-11 · 60 (10) · 1276-1292
DOI: 10.1111/apt.18315 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 05.10.2024. Verfasst von Maria Manuela Estevinho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Unidade Local de Saúde Gaia Espinho, Vila Nova de Gaia, Portugal. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Background
Histology has prognostic value in ulcerative colitis (UC). However, direct comparisons of histological endpoints are lacking.
Aim
To perform a network meta‐analysis (NMA) to compare histological endpoints with biologics and small molecules.
Methods
We searched four databases up until July 2024 for randomised controlled trials (RCTs) on advanced therapies for moderate‐to‐severe UC reporting histological endpoints. Outcomes included histological improvement or remission, and histo‐endoscopic improvement after induction or during maintenance. We used a random‐effects frequentist model and have reported outcomes as relative risk and 95% confidence interval. We estimated relative drug efficacy with the P ‐score. We conducted subgroup analysis by trial phase and evaluated risk of bias and evidence certainty.
Results
We included 24 RCTs (15 therapies, 8874 patients). Nineteen provided data on induction and 10 on maintenance; outcome definitions were similar. Etrasimod 2 mg/day ranked highest in achieving histologic improvement ( P ‐score 0.98) and remission ( P ‐score 0.90) following induction. Globally, guselkumab 200–400 mg ranked first for histo‐endoscopic improvement, while etrasimod 2 mg/day and upadacitinib 45 mg/day were superior in the subgroup analysis. During maintenance, upadacitinib 30 mg/day was superior in achieving histologic improvement and remission ( P ‐score 0.88 for both) and histo‐endoscopic improvement ( P ‐score 0.94). Etrasimod 2 mg/day ranked second for histologic remission ( P ‐score 0.70) and histo‐endoscopic improvement ( P ‐score 0.73), while mirikizumab 200 mg/month ranked second for histologic improvement.
Conclusion
These results support the ability of small molecules to achieve stringent endpoints in moderate‐to‐severe UC. Histological outcome data for biologics was sparser, particularly during maintenance. Head‐to‐head RCTs are imperative to better inform clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Unidade Local de Saúde Gaia Espinho, Vila Nova de Gaia, Portugal.
- Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
- Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Porto, Portugal.
- Department of Clinical Pharmacology, Unidade Local de Saúde de São, João, Portugal.
- Division of Gastroenterology, Western University, London, Ontario, Canada.
- Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
ORCID-Profile: Maria Manuela Estevinho, Virginia Solitano, Laurent Peyrin-Biroulet, Silvio Danese, Vipul Jairath, Fernando Magro
Zitieren
APA
Estevinho, M. M., Sousa-Pinto, B., Moreira, P. L., Solitano, V., Mesquita, P., Costa, C., Peyrin-Biroulet, L., Danese, S., Jairath, V., & Magro, F. (2024). Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 60(10), 1276-1292. https://doi.org/10.1111/apt.18315
Vancouver
Estevinho MM, Sousa-Pinto B, Moreira PL, Solitano V, Mesquita P, Costa C, et al. Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2024;60(10):1276-1292. doi:10.1111/apt.18315
BibTeX
@article{Estevinho2024,
author = {Estevinho, Maria Manuela and Sousa-Pinto, Bernardo and Moreira, Paula Leão and Solitano, Virginia and Mesquita, Pedro and Costa, Catarina and Peyrin-Biroulet, Laurent and Danese, Silvio and Jairath, Vipul and Magro, Fernando},
title = {Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {10},
pages = {1276--1292},
doi = {10.1111/apt.18315}
}
EUVIMED